基因測序市場－全球產業規模、佔有率、趨勢、機會、預測：按序列、技術、應用、最終用戶、地區和競爭格局分類，2021-2031年

全球基因組定序市場預計將大幅擴張，從 2025 年的 205.5 億美元成長到 2031 年的 715.4 億美元，複合年成長率為 23.11%。

這一成長主要得益於測序成本的下降以及基因組數據在精準醫療中用於個人化治療的日益普及。全球基因組與健康聯盟等組織持續管理數百萬個基因組資料集，進一步凸顯了定序技術在全球健康領域的應用日益廣泛且效用。然而，資料隱私和高度敏感的遺傳資訊的倫理處理等重大挑戰也阻礙了這一強勁成長。海量基因組資料的安全儲存和嚴格的監管要求可能導致操作複雜化，並阻礙定序工作流程在臨床環境中的順利實施。

市場促進因素

基因測序市場的主要驅動力是全球癌症和罕見遺傳疾病發生率的不斷上升，這些疾病需要先進的診斷和治療方法。臨床醫生越來越依賴基因組分析進行腫瘤精準醫療和罕見疾病管理，這顯著擴大了定序需求，美國預計到2025年將新增超過204.1萬例癌症病例便印證了這一點。如此巨大的疾病負擔凸顯了擴充性定序方案的必要性，以促進個人化治療並改善全球患者的治療效果。同時，定序成本的持續下降和可及性的提高使得基因組數據更加普及，加速了大規模人口生物銀行的建造及其在臨床實踐中的應用。科技進步降低了經濟門檻，推動了大規模研究舉措的發展，英國生物樣本庫近50萬個全基因組序列的成功就是一個例子。此外，政府投資，例如英國向生命科學製造業撥款5.2億英鎊，進一步加強了定序基礎設施的建設。

市場挑戰

全球基因測序市場成長面臨的主要挑戰之一是迫切需要健全的資料隱私管理和對敏感遺傳資訊的合乎倫理的處理。隨著定序量的增加，資料外洩和未授權存取個人基因組資料的風險也隨之上升，這需要採取嚴格的安全措施，但也使資料共用和儲存變得更加複雜。各機構必須應對複雜的國際法規，導致營運延誤、合規成本增加，最終阻礙定序順利融入臨床工作流程。這些隱私和安全問題極為嚴重，41%的生命科學專業人士認為這是2024年採用數位化實驗室技術的主要障礙。這項擔憂凸顯了市場參與企業在平衡基因組數據的臨床效用與患者隱私保護這一基本要求方面所面臨的困境，最終阻礙了創新資源的分配，並減緩了市場擴張。

市場趨勢

人工智慧 (AI) 和機器學習的融合，透過解決資料解讀的關鍵瓶頸，正在顯著改變市場格局。隨著定序處理能力的提升，用於快速變異檢測和臨床註釋的演算法解決方案對於處理大量原始資料至關重要，能夠顯著縮短診斷時間，並實現重症監護中的近即時應用。例如，將 AI 整合到 Illumina 的 DRAGEN v4.4 軟體中，已將結構變異識別準確率提高了 30%，從而增強了基因組分析結果的臨床效用。同時，第三代長讀長定序技術的應用正在加速，克服了傳統短讀長定序平台的局限性，從而拓展了市場。這些技術能夠對長 DNA 區域定序而不會發生片段化，從而能夠準確檢測出以往難以發現的大規模結構變異和複雜重複區域。這項技術優勢正在推動研究和臨床領域對全面基因組圖譜的強勁商業性需求，牛津奈米孔技術公司 (Oxford Nanopore Technologies) 的銷售額成長 11% 便印證了這一點。這反映了全球對該公司基於奈米孔的長讀長定定序解決方案的需求。

目錄

第1章概述

第2章：調查方法

第3章執行摘要

第4章：客戶心聲

第5章：全球基因測序市場展望

• 市場規模及預測
  • 按金額
• 市佔率及預測
  • 序列目標核苷酸（DNA 與 RNA）
  • 按技術（次世代定序、PCR、微陣列技術等）
  • 按應用領域（診斷、藥物發現與開發、精準醫療等）
  • 按最終用戶（學術和研究機構、製藥和生物技術公司、醫院和診所等）
  • 按地區
  • 按公司（2025 年）
• 市場地圖

第6章：北美基因測序市場展望

• 市場規模及預測
• 市佔率及預測
• 北美洲：國別分析
  • 美國
  • 加拿大
  • 墨西哥

第7章：歐洲基因測序市場展望

• 市場規模及預測
• 市佔率及預測
• 歐洲：國別分析
  • 德國
  • 法國
  • 英國
  • 義大利
  • 西班牙

第8章：亞太地區基因測序市場展望

• 市場規模及預測
• 市佔率及預測
• 亞太地區：國別分析
  • 中國
  • 印度
  • 日本
  • 韓國
  • 澳洲

第9章：中東和非洲基因測序市場展望

• 市場規模及預測
• 市佔率及預測
• 中東與非洲：國別分析
  • 沙烏地阿拉伯
  • 阿拉伯聯合大公國
  • 南非

第10章：南美洲基因測序市場展望

• 市場規模及預測
• 市佔率及預測
• 南美洲：國別分析
  • 巴西
  • 哥倫比亞
  • 阿根廷

第11章 市場動態

• 促進因素
• 任務

第12章 市場趨勢與發展

• 併購
• 產品發布
• 近期趨勢

第13章：全球基因測序市場：SWOT分析

第14章：波特五力分析

• 產業競爭
• 新進入者的潛力
• 供應商的議價能力
• 顧客權力
• 替代品的威脅

第15章 競爭格局

• Illumina, Inc
• Thermo Fisher Scientific Inc
• F. Hoffmann-La Roche Ltd
• Oxford Nanopore Technologies plc
• BGI Genomics Co., Ltd
• QIAGEN NV
• Pacific Biosciences of California, Inc
• PerkinElmer, Inc
• Agilent Technologies, Inc
• Macrogen, Inc

第16章 策略建議

第17章：關於研究公司及免責聲明

The global genome sequencing market is poised for significant expansion, projected to reach USD 71.54 Billion by 2031 from USD 20.55 Billion in 2025, demonstrating a 23.11% CAGR. This growth is primarily fueled by decreasing sequencing costs and the increasing integration of genomic data into precision medicine for personalized treatments. The ongoing stewardship of millions of genomes by organizations like the Global Alliance for Genomics and Health further highlights the growing adoption and utility of sequencing technologies in global health.\nHowever, this robust growth is tempered by substantial challenges related to data privacy and the ethical handling of sensitive genetic information. The need for secure storage and strict regulatory compliance for the vast amounts of genomic data introduces operational complexities, potentially hindering the smooth implementation of sequencing workflows in clinical settings.

Market Driver

The genome sequencing market is primarily driven by the increasing global incidence of cancer and rare genetic disorders, which demand advanced diagnostic and therapeutic approaches. Clinicians' growing reliance on genomic profiles for precision medicine in oncology and rare disease management has significantly amplified the need for sequencing, evidenced by projections such as over 2,041,000 new cancer cases in the United States in 2025. This substantial disease burden highlights the crucial requirement for scalable sequencing solutions to facilitate personalized treatment and enhance patient outcomes worldwide.\nConcurrently, the ongoing reduction in sequencing costs and enhanced accessibility are making genomic data more widely available, fostering population-scale biobanking and expanded clinical integration. Technological advancements have lowered financial hurdles, enabling large-scale research initiatives, as demonstrated by the successful analysis of nearly half a million whole genomes from the UK Biobank, while government investments, such as the UK's £520 million allocation for life sciences manufacturing, further bolster accessible sequencing infrastructure.

Market Challenge

A significant challenge impeding the global genome sequencing market's growth is the critical need for robust data privacy management and ethical handling of sensitive genetic information. With escalating sequencing volumes, the potential for data breaches and unauthorized access to personal genomic data increases, demanding stringent security measures that complicate data sharing and storage. Organizations must navigate complex international regulations, leading to operational delays and higher compliance costs, which in turn hinder the smooth incorporation of sequencing into clinical workflows.\nThese privacy and security concerns are substantial, with 41% of life science professionals identifying them as a major barrier to adopting digital laboratory technologies in 2024. This apprehension underscores the difficulty market participants face in balancing the clinical utility of genomic data with the essential requirement to protect patient confidentiality, ultimately diverting resources from innovation and slowing market expansion.

Market Trends

The integration of Artificial Intelligence and Machine Learning for automated genomic data analysis is profoundly transforming the market by addressing the critical bottleneck of data interpretation. As sequencing throughput increases, the overwhelming volume of raw data necessitates algorithmic solutions for rapid variant calling and clinical annotation, significantly reducing turnaround times for diagnostics and enabling near real-time applications in critical care. For example, AI integration in Illumina's DRAGEN v4.4 software enhanced structural variant calling accuracy by 30%, improving the clinical utility of genomic results.\nConcurrently, the accelerated adoption of third-generation long-read sequencing technologies is expanding the market by overcoming the limitations of traditional short-read platforms. These technologies allow for sequencing long DNA stretches without fragmentation, enabling precise detection of large structural variants and complex repetitive regions previously missed. This technical advantage is fueling strong commercial demand across research and clinical sectors seeking comprehensive genomic maps, evidenced by Oxford Nanopore Technologies' 11% revenue increase, reflecting global demand for its nanopore-based long-read sequencing solutions.

Key Market Players

• Illumina, Inc
• Thermo Fisher Scientific Inc
• F. Hoffmann-La Roche Ltd
• Oxford Nanopore Technologies plc
• BGI Genomics Co., Ltd
• QIAGEN N.V
• Pacific Biosciences of California, Inc
• PerkinElmer, Inc
• Agilent Technologies, Inc
• Macrogen, Inc

Report Scope

In this report, the Global Genome Sequencing Market has been segmented into the following categories, in addition to the industry trends which have also been detailed below:

Genome Sequencing Market, By Nucleotide Sequenced

• DNA
• RNA

Genome Sequencing Market, By Technique

• Next Generation Sequencing
• PCR
• Microarray Technology
• Others

Genome Sequencing Market, By Application

• Diagnostics
• Drug Discovery & Development
• Precision Medicine
• Others

Genome Sequencing Market, By End User

• Academic & Research Institutions
• Pharmaceutical & Biotechnology Companies
• Hospitals & Clinics
• Others

Genome Sequencing Market, By Region

• North America
  • United States
  • Canada
  • Mexico
• Europe
  • France
  • United Kingdom
  • Italy
  • Germany
  • Spain
• Asia Pacific
  • China
  • India
  • Japan
  • Australia
  • South Korea
• South America
  • Brazil
  • Argentina
  • Colombia
• Middle East & Africa
  • South Africa
  • Saudi Arabia
  • UAE

Competitive Landscape

Company Profiles: Detailed analysis of the major companies present in the Global Genome Sequencing Market.

Available Customizations:

Global Genome Sequencing Market report with the given market data, TechSci Research offers customizations according to a company's specific needs. The following customization options are available for the report:

Company Information

• Detailed analysis and profiling of additional market players (up to five).

Table of Contents

1. Product Overview

• 1.1. Market Definition
• 1.2. Scope of the Market
  • 1.2.1. Markets Covered
  • 1.2.2. Years Considered for Study
  • 1.2.3. Key Market Segmentations

2. Research Methodology

• 2.1. Objective of the Study
• 2.2. Baseline Methodology
• 2.3. Key Industry Partners
• 2.4. Major Association and Secondary Sources
• 2.5. Forecasting Methodology
• 2.6. Data Triangulation & Validation
• 2.7. Assumptions and Limitations

3. Executive Summary

• 3.1. Overview of the Market
• 3.2. Overview of Key Market Segmentations
• 3.3. Overview of Key Market Players
• 3.4. Overview of Key Regions/Countries
• 3.5. Overview of Market Drivers, Challenges, Trends

4. Voice of Customer

5. Global Genome Sequencing Market Outlook

• 5.1. Market Size & Forecast
  • 5.1.1. By Value
• 5.2. Market Share & Forecast
  • 5.2.1. By Nucleotide Sequenced (DNA v/s RNA)
  • 5.2.2. By Technique (Next Generation Sequencing, PCR, Microarray Technology, Others)
  • 5.2.3. By Application (Diagnostics, Drug Discovery & Development, Precision Medicine, Others)
  • 5.2.4. By End User (Academic & Research Institutions, Pharmaceutical & Biotechnology Companies, Hospitals & Clinics, Others)
  • 5.2.5. By Region
  • 5.2.6. By Company (2025)
• 5.3. Market Map

6. North America Genome Sequencing Market Outlook

• 6.1. Market Size & Forecast
  • 6.1.1. By Value
• 6.2. Market Share & Forecast
  • 6.2.1. By Nucleotide Sequenced
  • 6.2.2. By Technique
  • 6.2.3. By Application
  • 6.2.4. By End User
  • 6.2.5. By Country
• 6.3. North America: Country Analysis
  • 6.3.1. United States Genome Sequencing Market Outlook
    • 6.3.1.1. Market Size & Forecast
      • 6.3.1.1.1. By Value
    • 6.3.1.2. Market Share & Forecast
      • 6.3.1.2.1. By Nucleotide Sequenced
      • 6.3.1.2.2. By Technique
      • 6.3.1.2.3. By Application
      • 6.3.1.2.4. By End User
  • 6.3.2. Canada Genome Sequencing Market Outlook
    • 6.3.2.1. Market Size & Forecast
      • 6.3.2.1.1. By Value
    • 6.3.2.2. Market Share & Forecast
      • 6.3.2.2.1. By Nucleotide Sequenced
      • 6.3.2.2.2. By Technique
      • 6.3.2.2.3. By Application
      • 6.3.2.2.4. By End User
  • 6.3.3. Mexico Genome Sequencing Market Outlook
    • 6.3.3.1. Market Size & Forecast
      • 6.3.3.1.1. By Value
    • 6.3.3.2. Market Share & Forecast
      • 6.3.3.2.1. By Nucleotide Sequenced
      • 6.3.3.2.2. By Technique
      • 6.3.3.2.3. By Application
      • 6.3.3.2.4. By End User

7. Europe Genome Sequencing Market Outlook

• 7.1. Market Size & Forecast
  • 7.1.1. By Value
• 7.2. Market Share & Forecast
  • 7.2.1. By Nucleotide Sequenced
  • 7.2.2. By Technique
  • 7.2.3. By Application
  • 7.2.4. By End User
  • 7.2.5. By Country
• 7.3. Europe: Country Analysis
  • 7.3.1. Germany Genome Sequencing Market Outlook
    • 7.3.1.1. Market Size & Forecast
      • 7.3.1.1.1. By Value
    • 7.3.1.2. Market Share & Forecast
      • 7.3.1.2.1. By Nucleotide Sequenced
      • 7.3.1.2.2. By Technique
      • 7.3.1.2.3. By Application
      • 7.3.1.2.4. By End User
  • 7.3.2. France Genome Sequencing Market Outlook
    • 7.3.2.1. Market Size & Forecast
      • 7.3.2.1.1. By Value
    • 7.3.2.2. Market Share & Forecast
      • 7.3.2.2.1. By Nucleotide Sequenced
      • 7.3.2.2.2. By Technique
      • 7.3.2.2.3. By Application
      • 7.3.2.2.4. By End User
  • 7.3.3. United Kingdom Genome Sequencing Market Outlook
    • 7.3.3.1. Market Size & Forecast
      • 7.3.3.1.1. By Value
    • 7.3.3.2. Market Share & Forecast
      • 7.3.3.2.1. By Nucleotide Sequenced
      • 7.3.3.2.2. By Technique
      • 7.3.3.2.3. By Application
      • 7.3.3.2.4. By End User
  • 7.3.4. Italy Genome Sequencing Market Outlook
    • 7.3.4.1. Market Size & Forecast
      • 7.3.4.1.1. By Value
    • 7.3.4.2. Market Share & Forecast
      • 7.3.4.2.1. By Nucleotide Sequenced
      • 7.3.4.2.2. By Technique
      • 7.3.4.2.3. By Application
      • 7.3.4.2.4. By End User
  • 7.3.5. Spain Genome Sequencing Market Outlook
    • 7.3.5.1. Market Size & Forecast
      • 7.3.5.1.1. By Value
    • 7.3.5.2. Market Share & Forecast
      • 7.3.5.2.1. By Nucleotide Sequenced
      • 7.3.5.2.2. By Technique
      • 7.3.5.2.3. By Application
      • 7.3.5.2.4. By End User

8. Asia Pacific Genome Sequencing Market Outlook

• 8.1. Market Size & Forecast
  • 8.1.1. By Value
• 8.2. Market Share & Forecast
  • 8.2.1. By Nucleotide Sequenced
  • 8.2.2. By Technique
  • 8.2.3. By Application
  • 8.2.4. By End User
  • 8.2.5. By Country
• 8.3. Asia Pacific: Country Analysis
  • 8.3.1. China Genome Sequencing Market Outlook
    • 8.3.1.1. Market Size & Forecast
      • 8.3.1.1.1. By Value
    • 8.3.1.2. Market Share & Forecast
      • 8.3.1.2.1. By Nucleotide Sequenced
      • 8.3.1.2.2. By Technique
      • 8.3.1.2.3. By Application
      • 8.3.1.2.4. By End User
  • 8.3.2. India Genome Sequencing Market Outlook
    • 8.3.2.1. Market Size & Forecast
      • 8.3.2.1.1. By Value
    • 8.3.2.2. Market Share & Forecast
      • 8.3.2.2.1. By Nucleotide Sequenced
      • 8.3.2.2.2. By Technique
      • 8.3.2.2.3. By Application
      • 8.3.2.2.4. By End User
  • 8.3.3. Japan Genome Sequencing Market Outlook
    • 8.3.3.1. Market Size & Forecast
      • 8.3.3.1.1. By Value
    • 8.3.3.2. Market Share & Forecast
      • 8.3.3.2.1. By Nucleotide Sequenced
      • 8.3.3.2.2. By Technique
      • 8.3.3.2.3. By Application
      • 8.3.3.2.4. By End User
  • 8.3.4. South Korea Genome Sequencing Market Outlook
    • 8.3.4.1. Market Size & Forecast
      • 8.3.4.1.1. By Value
    • 8.3.4.2. Market Share & Forecast
      • 8.3.4.2.1. By Nucleotide Sequenced
      • 8.3.4.2.2. By Technique
      • 8.3.4.2.3. By Application
      • 8.3.4.2.4. By End User
  • 8.3.5. Australia Genome Sequencing Market Outlook
    • 8.3.5.1. Market Size & Forecast
      • 8.3.5.1.1. By Value
    • 8.3.5.2. Market Share & Forecast
      • 8.3.5.2.1. By Nucleotide Sequenced
      • 8.3.5.2.2. By Technique
      • 8.3.5.2.3. By Application
      • 8.3.5.2.4. By End User

9. Middle East & Africa Genome Sequencing Market Outlook

• 9.1. Market Size & Forecast
  • 9.1.1. By Value
• 9.2. Market Share & Forecast
  • 9.2.1. By Nucleotide Sequenced
  • 9.2.2. By Technique
  • 9.2.3. By Application
  • 9.2.4. By End User
  • 9.2.5. By Country
• 9.3. Middle East & Africa: Country Analysis
  • 9.3.1. Saudi Arabia Genome Sequencing Market Outlook
    • 9.3.1.1. Market Size & Forecast
      • 9.3.1.1.1. By Value
    • 9.3.1.2. Market Share & Forecast
      • 9.3.1.2.1. By Nucleotide Sequenced
      • 9.3.1.2.2. By Technique
      • 9.3.1.2.3. By Application
      • 9.3.1.2.4. By End User
  • 9.3.2. UAE Genome Sequencing Market Outlook
    • 9.3.2.1. Market Size & Forecast
      • 9.3.2.1.1. By Value
    • 9.3.2.2. Market Share & Forecast
      • 9.3.2.2.1. By Nucleotide Sequenced
      • 9.3.2.2.2. By Technique
      • 9.3.2.2.3. By Application
      • 9.3.2.2.4. By End User
  • 9.3.3. South Africa Genome Sequencing Market Outlook
    • 9.3.3.1. Market Size & Forecast
      • 9.3.3.1.1. By Value
    • 9.3.3.2. Market Share & Forecast
      • 9.3.3.2.1. By Nucleotide Sequenced
      • 9.3.3.2.2. By Technique
      • 9.3.3.2.3. By Application
      • 9.3.3.2.4. By End User

10. South America Genome Sequencing Market Outlook

• 10.1. Market Size & Forecast
  • 10.1.1. By Value
• 10.2. Market Share & Forecast
  • 10.2.1. By Nucleotide Sequenced
  • 10.2.2. By Technique
  • 10.2.3. By Application
  • 10.2.4. By End User
  • 10.2.5. By Country
• 10.3. South America: Country Analysis
  • 10.3.1. Brazil Genome Sequencing Market Outlook
    • 10.3.1.1. Market Size & Forecast
      • 10.3.1.1.1. By Value
    • 10.3.1.2. Market Share & Forecast
      • 10.3.1.2.1. By Nucleotide Sequenced
      • 10.3.1.2.2. By Technique
      • 10.3.1.2.3. By Application
      • 10.3.1.2.4. By End User
  • 10.3.2. Colombia Genome Sequencing Market Outlook
    • 10.3.2.1. Market Size & Forecast
      • 10.3.2.1.1. By Value
    • 10.3.2.2. Market Share & Forecast
      • 10.3.2.2.1. By Nucleotide Sequenced
      • 10.3.2.2.2. By Technique
      • 10.3.2.2.3. By Application
      • 10.3.2.2.4. By End User
  • 10.3.3. Argentina Genome Sequencing Market Outlook
    • 10.3.3.1. Market Size & Forecast
      • 10.3.3.1.1. By Value
    • 10.3.3.2. Market Share & Forecast
      • 10.3.3.2.1. By Nucleotide Sequenced
      • 10.3.3.2.2. By Technique
      • 10.3.3.2.3. By Application
      • 10.3.3.2.4. By End User

11. Market Dynamics

• 11.1. Drivers
• 11.2. Challenges

12. Market Trends & Developments

• 12.1. Merger & Acquisition (If Any)
• 12.2. Product Launches (If Any)
• 12.3. Recent Developments

13. Global Genome Sequencing Market: SWOT Analysis

14. Porter's Five Forces Analysis

• 14.1. Competition in the Industry
• 14.2. Potential of New Entrants
• 14.3. Power of Suppliers
• 14.4. Power of Customers
• 14.5. Threat of Substitute Products

15. Competitive Landscape

• 15.1. Illumina, Inc
  • 15.1.1. Business Overview
  • 15.1.2. Products & Services
  • 15.1.3. Recent Developments
  • 15.1.4. Key Personnel
  • 15.1.5. SWOT Analysis
• 15.2. Thermo Fisher Scientific Inc
• 15.3. F. Hoffmann-La Roche Ltd
• 15.4. Oxford Nanopore Technologies plc
• 15.5. BGI Genomics Co., Ltd
• 15.6. QIAGEN N.V
• 15.7. Pacific Biosciences of California, Inc
• 15.8. PerkinElmer, Inc
• 15.9. Agilent Technologies, Inc
• 15.10. Macrogen, Inc

16. Strategic Recommendations

17. About Us & Disclaimer